The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Future management of CTCL
Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the future of management of cutaneous T-cell lymphoma (CTCL), commenting on differences in the treatment of early- and late-stage disease. Prof. Papadavid comments on the use of topical treatments in early treatment and the use of systemic treatments in later-stage disease or patients with poor prognosis. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
